<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01369771</url>
  </required_header>
  <id_info>
    <org_study_id>S001-2010</org_study_id>
    <secondary_id>2010-021039-14</secondary_id>
    <nct_id>NCT01369771</nct_id>
  </id_info>
  <brief_title>The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma</brief_title>
  <official_title>An Open-label, Phase IV, Pilot Study, to Evaluate Confocal Microscopic Findings of Cornea, Ocular Signs and Symptoms in Patients With OH or OAG Switching From Latanoprost 0.005% to Preservative Free Tafluprost 0.0015% Eye Drops</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FinnMedi Oy</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tampere University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Laboratory and Pharmacy Public Utility of the Pirkanmaa Hospital District</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>FinnMedi Oy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate corneal confocal microscopic findings, ocular&#xD;
      signs and symptoms in patients on treatment with the preserved prostaglandin analogue&#xD;
      latanoprost 0.005% eye drops (Xalatan®) and after the switch to preservative-free&#xD;
      prostaglandin analog tafluprost 0.0015% eye drops (Taflotan®). Patients who have been using&#xD;
      latanoprost as their prior medication (at least 6 months) and who fulfil all the inclusion&#xD;
      criteria including the specified ocular symptoms and signs, will switch from latanoprost&#xD;
      0.005% eye drops to the assigned preservative-free tafluprost 0.0015% eye drops for twelve&#xD;
      (12) months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary outcome measures:&#xD;
&#xD;
        1. Change from screening in corneal confocal microscopic findings at month 12&#xD;
&#xD;
        2. Change from screening in ocular symptoms upon non-instillation at month 12&#xD;
&#xD;
        3. Change from screening in ocular signs at month 12&#xD;
&#xD;
           Safety and QoL variables:&#xD;
&#xD;
        4. Descriptive statistics, identification of change(s) from screening&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from screening in corneal confocal microscopic findings at month 12</measure>
    <time_frame>Baseline and Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from screening in ocular symptoms and signs upon non-instillation</measure>
    <time_frame>Baseline and Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Open-Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Tafluprost 0.0015%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open, one arm study. Patients who have been using latanoprost 0.005% eye drops (Xalatan®) as their prior medication (at least 6 months) and who fulfil all the inclusion criteria including the specified ocular symptoms and signs, will switch from latanoprost to the assigned preservative-free tafluprost 0.0015% (Taflotan®)eye drops for twelve (12) months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tafluprost 0.0015%</intervention_name>
    <description>Eye Drops, Solution. Topical Use. One single-unit dose pipet of 0.3 ml solution including 0.0015 mg/ ml of Tafluprost once daily in the affected eye(s)for 12 months.</description>
    <arm_group_label>Tafluprost 0.0015%</arm_group_label>
    <other_name>Taflotan®</other_name>
    <other_name>Taflotan sine®</other_name>
    <other_name>Saflutan®</other_name>
    <other_name>Saflutan Conserveermiddelvrij®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have provided a written informed consent&#xD;
&#xD;
          -  Aged 18 years or more&#xD;
&#xD;
          -  A diagnosis of ocular hypertension or open-angle glaucoma (either POAG or capsular&#xD;
             glaucoma) in one or both eyes, for which the patient has been regularly using&#xD;
             latanoprost 0.005% (Xalatan®) for at least six months before Screening (confirmed in&#xD;
             anamnesis)&#xD;
&#xD;
          -  In the Screening visit evaluation, the presence of:&#xD;
&#xD;
        At least two ocular symptoms considered for the two eyes together&#xD;
        (irritation/burning/stinging, foreign body sensation, tearing, itching or dry eye&#xD;
        sensation) of at least mild severity (grade ≥ 2) upon non-instillation OR One ocular&#xD;
        symptom of at least mild severity (grade ≥ 2) upon non-instillation AND&#xD;
&#xD;
        At least one of the following ocular signs in either eye with prior treatment:&#xD;
&#xD;
        Fluorescein tear break-up time (fBUT): less than 10 seconds&#xD;
&#xD;
        Corneal and conjunctival fluorescein staining:&#xD;
&#xD;
        Corneal fluorescein staining score of at least grade I OR Combined nasal and temporal&#xD;
        staining scores of at least grade II Blepharitis: of at least mild severity (grade ≥ 1)&#xD;
        Conjunctival redness/hyperemia: of at least mild severity (grade 1) Tear production: 10 mm&#xD;
        or less on Schirmer test&#xD;
&#xD;
          -  A best corrected ETDRS visual acuity score of +0.6 logMAR or better in both eyes&#xD;
&#xD;
          -  Negative pregnancy test result at the screening visit, or, consistently and correctly&#xD;
             used reliable method of contraception during the study&#xD;
&#xD;
          -  Are willing to follow instructions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant, nursing or planning a pregnancy, or females of childbearing&#xD;
             potential who are not using a reliable method of contraception&#xD;
&#xD;
          -  Anterior chamber angle in either eye to be treated less than grade 2 according to&#xD;
             Schaffer classification as measured by gonioscopy&#xD;
&#xD;
          -  Any corneal abnormality or other condition preventing reliable applanation tonometry,&#xD;
             including prior refractive eye surgery&#xD;
&#xD;
          -  IOP greater than 22 mmHg at 15:00 IOP measurement in either eye at Screening/Baseline&#xD;
             visit&#xD;
&#xD;
          -  Use of preserved eye drops (other than latanoprost) including artificial tears at&#xD;
             screening or within two weeks prior to screening visit&#xD;
&#xD;
          -  Diagnosis of angle-closure glaucoma or secondary glaucoma other than capsular glaucoma&#xD;
             in either eye&#xD;
&#xD;
          -  Suspected contraindication to tafluprost therapy (hypersensitivity to tafluprost or&#xD;
             any of the excipients)&#xD;
&#xD;
          -  Glaucoma filtration surgery or any other ocular surgery (including ocular laser&#xD;
             procedures) within 6 months prior to Screening in eye(s) to be treated with study&#xD;
             medication&#xD;
&#xD;
          -  Use of contact lenses at Screening or during the study&#xD;
&#xD;
          -  Any ocular (e.g. aphakia, pseudophakia with torn posterior lens capsule2 or anterior&#xD;
             chamber lenses,known risk factors for cystoid macular oedema or iritis/uveitis),&#xD;
             systemic or psychiatric disease/condition (e.g.uncontrolled arterial hypertension,&#xD;
             diabetes) that may put the patient at a significant risk or may confound the study&#xD;
             results or may interfere significantly with the patient's participation in the study&#xD;
             as judged by the investigator&#xD;
&#xD;
          -  Current alcohol or drug abuse&#xD;
&#xD;
          -  Current participation in another clinical trial involving an investigational&#xD;
             drug/device, or participation in such a trial within the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hannu Uusitalo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trial Center, FinnMedi Oy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FinnMedi Oy, Clinical Trial Center</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa district</state>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>July 5, 2010</study_first_submitted>
  <study_first_submitted_qc>June 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <last_update_submitted>October 27, 2014</last_update_submitted>
  <last_update_submitted_qc>October 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Confocal microscopic findings</keyword>
  <keyword>Ocular Hypertension</keyword>
  <keyword>Open-Angle Glaucoma</keyword>
  <keyword>Preservative-free eye drops</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

